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Mesenchymal stem/stromal cells have unique properties favorable to their use in clinical
practice and have been studied for cardiac repair. However, these cells are larger than coro-
nary microvessels and there is controversy about the risk of embolization and microinfarc-
tions, which could jeopardize the safety and efficacy of intracoronary route for their delivery.
The index of microcirculatory resistance (IMR) is an invasive method for quantitatively
assessing the coronary microcirculation status.
Objectives
To examine heart microcirculation after intracoronary injection of mesenchymal stem/
stromal cells with the index of microcirculatory resistance.
Methods
Healthy swine were randomized to receive by intracoronary route either 30x106 MSC or the
same solution with no cells (1% human albumin/PBS) (placebo). Blinded operators took
coronary pressure and flow measurements, prior to intracoronary infusion and at 5 and 30
minutes post-delivery. Coronary flow reserve (CFR) and the IMR were compared between
groups.
Results
CFR and IMR were done with a variance within the 3 transit time measurements of 6% at
rest and 11% at maximal hyperemia. After intracoronary infusion there were no significant
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differences in CFR. The IMR was significantly higher in MSC-injected animals (at 30 min-
utes, 14.2U vs. 8.8U, p = 0.02) and intragroup analysis showed a significant increase of
112% from baseline to 30 minutes after cell infusion, although no electrocardiographic
changes or clinical deterioration were noted.
Conclusion
Overall, this study provides definitive evidence of microcirculatory disruption upon intracor-
onary administration of mesenchymal stem/stromal cells, in a large animal model closely
resembling human cardiac physiology, function and anatomy.
Introduction
Cardiovascular diseases represent the leading cause of death in developed countries despite
major advances in its treatment and prevention, and these are also a major cause of disability,
lost productivity and increased health costs worldwide [1]. Most cardiovascular diseases are
associated with loss of functional cardiomyocytes, which are not replaced due to the limited
regenerative capacity intrinsic to the heart. In recent years, cell-based therapy has been pre-
sented as a potential therapeutic strategy for cardiac regeneration [2].
Mesenchymal stem/stromal cells (MSC), in particular, have emerged as a promising candi-
date for cell-based therapies [3]. These cells have important intrinsic features for therapeutic
settings namely: easy isolation from a small aspirate of bone marrow, adipose tissue or from
other sources of perinatal origin (e.g. umbilical cord) and high in vitro expansion potential
[4,5], multilineage differentiation capacity [6], ability to modulate immune responses and
secrete various cytokines that play a role in processes such as angiogenesis, inflammation, cel-
lular migration and apoptosis [7]. Although there is no clear evidence that MSC can differenti-
ate into myocardial cells [8], the advantages of a MSC-based therapy could lie in the
immunomodulatory effects mediated by these cells, as well as the ability of MSC to promote
growth, survival or differentiation of other cells in the damaged myocardial area through para-
crine mechanisms [9]. These properties have encouraged pre-clinical and clinical research to
explore the potential role of MSC as a cell-based treatment for heart disease [3].
The use of intracoronary (IC) artery infusion in cell-based therapy is based on standard
knowledge and catheterization techniques allowing direct delivery of a large number of cells
into myocardial regions. With this advantage, the IC route has been the most used delivery
method of hematopoietic cells (i.e. mononucleated cells, MNC), including stem/progenitor
cells, in cardiovascular cell-based research [2]. However, its use for administration of MSC is
still a matter for debate. With a diameter of 10–20 μm, MSC are larger than heart capillaries
(5–10 μm) and there is the risk of microcirculation obstruction [10]. The potential safety issues
of intracoronary MSC-based therapies, namely microinfarctions, should be addressed with
solid pre-clinical research, as current data is limited and controversial.
Coronary flow reserve (CFR) is the maximum increase in blood flow through the coronary
arteries above the normal resting volume and is measured to assess the flow in the epicardial
artery and in the microcirculatory bed. The index of microcirculation resistance (IMR), allows
a quantitative, invasive, and real-time evaluation of the coronary microcirculation status inde-
pendently of the epicardial vessel. IMR is defined as distal coronary pressure multiplied by the
hyperemic mean transit time (mm Hg  seconds, or units [U]) [11]. Current interventional car-
diology techniques allow for the simultaneous measurement of CFR and IMR with a pressure-
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temperature sensor-tipped wire. Mean transit time is derived from thermodilution after IC
injection of room-temperature saline and it correlates to the coronary absolute flow. Disrup-
tion of the microvascular bed is associated with a significant increase in IMR and this can be
determined immediately after an IC intervention using the same catheter based procedure.
IMR assessment is expected to clarify how MSC IC infusion affects heart microcirculation.
Objectives
The overall goal of the present work was to study the IC artery delivery of human MSC in a
large animal model—swine—closely resembling coronary circulation and arterial anatomy in
humans. Specifically, this study was designed to examine heart microcirculation damage with
IMR assessment after MSC IC injection in the animals compared to a control group (i.e. no
cells administered). We also evaluated the differences in hemodynamic, electrocardiographic
and coronary epicardial artery flow parameters upon administration of MSC.
Materials and Methods
Overview
Eighteen swine (males Duroc and females F1 Large White X Landrace) with a weight of 25 to
40 Kg (31 ± 5 Kg) were randomized to receive either (i) 1 million MSC/kg corresponding to
approximately 30x106 MSC resuspended in phosphate buffered saline (PBS) supplemented
with human albumin (HA), or (ii) cell-free PBS/HA solution (placebo—control group). All
procedures were the same between the two groups. The operators performing all measure-
ments were blinded to which group the animal belonged to.
MSC preparation
MSC used in this study were part of the cell bank available at the Stem Cell Bioengineering and
Regenerative Medicine Laboratory, Instituto Superior Técnico (IST-iBB). These cells were iso-
lated from Bone marrow (BM) aspirates from healthy donors upon informed consent accord-
ing to the protocol described by dos Santos and co-workers [12]. Briefly, the mononuclear
fraction was separated using a Ficoll gradient and cells were isolated based on their ability to
adhere to tissue culture plastic (polystyrene) upon cultivation in low-glucose Dulbecco’s modi-
fied Eagle’s medium (DMEM) (Gibco) supplemented (10%) with MSC-qualified fetal bovine
serum (FBS) (Hyclone). For cell preparation in the present study, multiple vials of BMMSC
from a single donor (kept cryopreserved in a liquid/vapour phase nitrogen tank) were thawed
and plated at 3000–6000 cells/cm2 on T-175 flasks (BD Falcon) using DMEM-10%FBS and
expanded upon consecutive passaging to reach the target cell doses for administration. Cells at
passages P5-P7 were used in the present study. Cell number and viability were assessed using
the Trypan Blue exclusion method (Gibco) and counting cells on a hemocytometer under an
optical microscope (Olympus).
MSC were characterized by flow cytometry using specific monoclonal antibodies according
to criteria defined in the literature [13]. Over 95% of the population should express CD73,
CD90 and CD105 and not express (less than 2%) CD14, CD19, CD31, CD34, CD45, CD80 and
HLA-DR. For this purpose, cells were incubated for 15 minutes in the dark with a panel of
mouse anti-human fluorescent-labeled monoclonal antibodies (all from BioLegend, except
anti-CD105 (Invitrogen)). Cells were then washed with PBS and analyzed by flow cytometry. A
minimum of 10 000 events were collected for each sample and the CellQuest™ software (Becton
Dickinson) was used for acquisition and analysis. The differentiation potential of MSC was
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tested using biochemical methods after in vitro induction of osteogenesis, adipogenesis, and
chondrogenesis using specific culture media.
In order to prepare administration, expanded cells were resuspended in a HA-containing
(1%) solution prepared by dilution (1:30) of a stock solution (30%, Albunorm, Octapharma) in
PBS. Multiple samples of cell suspensions were observed under optical microscopy at different
time points upon resuspension to verify the occurrence of cell aggregation. Cells were trans-
ported from the cell culture laboratory at IST-iBB to animal facilities at room temperature and
administered within 2 hours.
Animal care and catheterization procedures. Animal procedures were approved by the
Ethical and Animal Welfare commission of the Veterinary Medical School, Universidade de
Lisboa, and the study was authorized by the national regulatory authorities. All handling and
care followed the European directive 2010/63/EU on the protection of animals used for scien-
tific purposes.
Animals fasted overnight prior to the experiments. Anesthesia was induced by intramuscu-
lar injection of azaperone (2 mg/kg), atropine (1 mg) and after 15 minutes, ketamine (20 mg/
kg). In the catheterization laboratory, a venous catheter (22 G) was placed in the marginal ear
vein, through which sodium thiopental (6 mg/kg) was injected. Anesthesia was maintained
with mechanical tracheal ventilation (tidal volume of 10 ml/kg) and inhaled isoflurane (2%).
After placing a 6F sheath in the femoral artery, anticoagulation was achieved with intravenous
heparin (300 U/ kg). Hemodynamic and electrocardiographic monitoring was maintained dur-
ing the entire experiment. Aorta and left ventricle pressure measurements were done with a 6F
pigtail catheter and for selective catheterization of the left main artery a 6F Amplatz left 0.75
was used. All heart catheterization procedures were conducted under fluoroscopy.
At the end of the experiment, animals that received MSC were euthanized with intravenous
sodium thiopental. Control animals were treated with intravenous carprofen (2 mg/kg) plus
amoxicillin (15mg/kg) and kept in 48 hours quarantine with no signs of suffering.
MSC delivery
After selective catheterization of the left main artery, a microcatheter FineCross™ (Terumo
Interventional Systems) was placed in the left anterior descending coronary artery (LAD), just
distal to the first diagonal branch and with the help of a .014 guiding wire BMW1 (Abbott
Vascular). Through its central lumen, the 20 cc solution was injected at a 4 cc / min constant
flow, using an oscillating infusion pump syringe to prevent cell aggregation. At the end, the
microcatheter was removed and a coronariography was performed to exclude dissections.
Coronary pressure and flow measurements
Measurements were taken prior to IC infusion and at 5 and 30 minutes post-delivery. A coro-
nary pressure wire, PressureWire™ Certus (St. Jude Medical), was calibrated and advanced to
the distal LAD, with the sensor located in the middle third of the coronary. The position of the
wire was maintained during the experiment.
A RadiAnalyzer™ Xpress interface and software (Radi Medical Systems, St. Jude Medical)
were used for pressure and mean transit time records. Thermodilution-derived mean transit
time was assessed after a rapid injection of 3 ml of room temperature saline (i.e. PBS/HA)
through the guiding catheter. Measurements were taken at resting and after maximal hyper-
emia induced with 10 mg IC papaverine. Three measurements were considered and the mean
vales were used for analysis. Distal coronary pressure was simultaneously recorded.
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CFR was defined as resting mean transit time divided by hyperemic mean transit time. IMR
was calculated distal coronary pressure multiplied by the hyperemic mean transit time (mm
Hg  seconds, or units [U]) (Fig 1).
Electrocardiographic, hemodynamic, and angiographic evaluation
Twelve-lead electrocardiograms (ECG) were done before heart catheterization and 30 minutes
after IC delivery of MSC or cell-free solution. Electrocardiographic monitoring was maintained
through the experiment. Heart rate, ventricular arrhythmias and ECG profile changes with evi-
dence of acute myocardial ischemia were assessed.
Intraventricular and aortic pressures were recorded at the beginning of the experiment and
30 minutes after IC infusion.
After selective catheterization of the left main artery, 0.5 mg of isossorbide dinitrate was
injected for coronary dilation. Left coronary angiograms were done with manual injection of
10 cc of iodine-based contrast media prior to IC infusion, immediately after and at 30 minutes.
Coronary epicardial flow was classified with the TIMI scoring system.
Statistical analysis
Data are presented as mean ± standard deviation. Normality was assessed using the Shapiro–
Wilk’s tests. Comparisons were made among control and MSC animal groups using Student's
t-test for independent variables, significance was set at the 0.05 level. Intragroup analysis was
done using repeated measures ANOVA model with post hoc paired t-tests with Bonferroni's
correction, and a corrected p value< 0.05 was taken as significant. Statistical analysis was per-
formed using site-licensed SPSS1 statistical software.
Results
For the purpose of this study, BM-derived MSC administered into the animals were previously
expanded onto tissue culture flasks through consecutive passaging and maintained their char-
acteristic spindle shape morphology (Fig 2A), immunophenotype (Fig 2B), as well as their mul-
tilineage differentiation ability (data not shown).
Hemodynamic parameters are presented in Table 1. There were no significant differences in
baseline parameters between MSC and control groups. After MSC injection there were no sig-
nificant changes in heart rate, left ventricular end-diastolic pressure and systolic aortic
Fig 1. Left coronary angiography and RadiAnalyzer™ Xpress interface display. The mean transit time
was estimated after a rapid IC injection of room temperature saline through the guiding catheter. Temperature
change is first detected at the proximal sensor, and then saline circulates in coronary artery and reaches the
distal sensor. The distal sensor of the pressure wire also assesses de distal pressure. IMR is calculated with
these two variables. Thermodilution curves could be seen at the bottom of the interface display (green and
yellow). In the middle, aortic pressure (red curve) and distal coronary pressure (green curve) are also shown.
LAD: left anterior descendent artery; CX: circumflex artery, IMR: index of microcirculatory resistance.
doi:10.1371/journal.pone.0139870.g001
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pressure. There was no significant coronary artery narrowing and all animals had TIMI 3
grade distal blood flow immediately after and at 30 minutes of IC infusion. During the proce-
dure no ST-segment elevation or ventricular arrhythmias were observed.
The variance within the 3 hyperemic transit time measurements was 6% at rest and 11% at
maximal hyperemia in the studied population (18 animals divided into two groups, n = 9). The
mean reduction in distal coronary pressure after IC papaverine was 18 ± 7.0 mmHg in control
animals and 14 ± 5.0 in MSC animals (p = 0.2), a relative decrease of 27% and 22%,
respectively.
The mean values of CFR and IMR are presented in Table 2. CFR and IMR were similar
between the 2 groups at baseline. After IC infusion there were no significant differences in
CFR, although a small decrease was observed in the MSC group. Concerning IMR, no signifi-
cant differences were observed at 5 minutes, but a significant increase was observed at 30 min-
utes in the MSC-injected animals (p = 0.02).
Fig 3 shows the results of IMR assessed at 5 and 30 minutes after intracoronary infusion. In
repeated measures ANOVA mean IMR differed statistically significantly between time points
in animals that received cells (F (2–16) = 8.925, p = 0.002). In these animals the baseline IMR
was 6.7 ± 0.6 U, and after IC infusion increased to 15.3 ± 2.8 U at 5 minutes (corresponding to
a 128% increase, p = 0.047) and to 14.2 ± 1.8 U at 30 minutes (112% increase, p = 0.008). In the
control group there was a barely detectable statistically significant difference in mean IMR (F
(2–16) = 3.897, p = 0.042), and the Bonferroni post hoc test did not reveal significant difference
between time points. The baseline IMR values in control animals was 8.1 ± 1.0 U, and after IC
infusion increased to 9.8 ± 1.0 U at 5 minutes (corresponding to a 21% increase, p = 0.085) and
to 8.8 ± 1 U at 30 minutes (9% increase, p = 0.898). All relevant data are presented in the sup-
porting information (S1 File).
Discussion
After several years of cardiovascular cell-based research, the optimal cell type for regenerating
the damaged myocardium and trigger neovascularization and angiogenesis, as well as the best
cell delivery route, have not been established yet.
Fig 2. Characterization of bonemarrow (BM)-derived mesenchymal stem/stromal cells (MSC) expanded on tissue culture flasks using DMEM
culture medium supplemented with 10% FBS. (A) Morphology of cultured cells assessed by optical microscopy. (B) Immunophenotype of cultured MSC
assessed by flow cytometry according to Materials and Methods description. Percentage (%) displayed in the upper right corner of each histogram indicates
the expression of each antigen.
doi:10.1371/journal.pone.0139870.g002
Table 1. Weight, baseline and post-delivery hemodynamic parameters inControl andMSC animals.
Means and standard deviation, differences assessed with Student's t-test for independent variables (n = 9).
CONTROL MSC P
Weight (kg) 31 ± 2 32 ± 2 0.8
Heart rate (bpm) 106 ± 5 100 ± 5 0.5
Aortic systolic pressure (mmHg) 98 ± 7 93± 3 0.4
End-diastolic LV1 pressure (mmHg) 7.7 ± 2 7.3 ± 2 0.7
Post-delivery heart rate (bpm) 114 ± 23 111 ± 15 0.7
Post-delivery aortic systolic pressure (mmHg) 96 ± 18 88± 13 0.3
Post-delivery end-diastolic LV1 pressure (mmHg) 8.3 ± 3 8.2 ± 3 0.9
1Left ventricle.
doi:10.1371/journal.pone.0139870.t001
Intracoronary Delivery of Human Mesenchymal/Stromal Stem Cells
PLOS ONE | DOI:10.1371/journal.pone.0139870 October 19, 2015 7 / 12
MSC in particular have been extensively investigated in cardiac regenerative therapy trials
during the past decade [14,15]. In pre-clinical studies these cells have been shown to engraft in
the heart, reduce infarction size and allow for an improvement in ventricle contractile function
in rodent [16,17] and larger animal models [18,19].
In the present work, we studied the IC delivery of human BM-derived MSC in a swine
model, closely resembling coronary circulation and arterial anatomy in humans. We chose to
Table 2. Coronary flow reserve and index of microcirculatory resistance inControl andMSC animals.
Means and standard deviation, differences assessed with Student's t-test for independent variables (n = 9).
CONTROL MSC P
Baseline CFR1 3.8 ± 1 4 ± 2 0.7
Baseline IMR2 (U) 8.1 ± 1 6.7 ± 0.6 0.3
Post-delivery CFR1—5 min. 3.6 ± 1 3 ± 2 0.5
Post-delivery CFR1—30 min. 3.8 ± 2 2.3 ± 1.5 0.06
Post-delivery IMR2—5 min. (U) 9.8 ± 1 15.3 ± 2.8 0.08
Post-delivery IMR2—30 min. (U) 8.8 ± 1 14.2 ± 1.8 0.02
1 Coronary ﬂow reserve
2 Index of microcirculatory resistance.
doi:10.1371/journal.pone.0139870.t002
Fig 3. The index of microcirculatory resistance—results at baseline, 5 and 30minutes. Baseline, 5 and 30 minutes post delivery IMR values are shown
for Control and MSC group (n = 9). Differences from baseline were assessed with repeated measures ANOVA and P-values are adjusted for multiple
comparisons (Bonferroni).
doi:10.1371/journal.pone.0139870.g003
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use culture-expanded, human BM-derived cells defined by the standards of the International
Society of Cellular Therapy (ISCT) [13], since these cells, despite representing a heterogeneous
cell population, have been widely exploited experimentally and in clinical trials. For instances,
Hare and co-workers reported in 2009 a double-blind controlled phase I study demonstrating
the safety of the intravenous route of MSC in patients with myocardial infarction [20]. More
recently, Bartunek and colleagues, in the C-Cure trial, demonstrated the safety associated with
signs of clinical benefit of MSC endomyocardial injections in patients with chronic heart failure
[21].
The IC cell delivery of MSC has proven to result in an increased cell engraftment within the
infarcted tissue of porcine compared to the intravenous route [22]. The comparison of IC
delivery versus the endocardial route is more controversial [22,23]. While IC delivery is based
on coronary procedures that are part of clinical practice nowadays, the endocardial administra-
tion of cells relies on more complex techniques that interventional cardiologists are not familiar
with. Nevertheless, despite the advantages of the IC route, there is apprehension about the size
of MSC and the possibility of microvascular obstruction [24,25], myocardial microinfarctions
[26], and decreased coronary flow [21] upon MSC delivery. In this context, preclinical data has
been controversial but some recent studies support the safety and clinical benefit of MSC IC
delivery [27,28,29].
It has been hypothesized that microcirculatory entrapment of MSC and their consequences
to coronary flow are probably dose related. For instance, Hong and colleagues performed an IC
dose escalating study in 3 pigs, injecting 1, 3, 10, 30, 100x106 of adipose-derived stem cells with
30 minute intervals [30]. Coronary blood was not changed at a cumulative dose of 14x106, but
further injections after cumulative dose of 44 x 106 were associated with a progressive decrease
in the coronary filling time culminating in hypokinesia of the anterior apical wall. With this
data in mind, we chose to use infusions of 30x106 MSC (roughly corresponding to 1x106 MSC/
kg) in the present study. This could be a suitable dose since there were no periprocedural com-
plications with IC infusion of MSC and no hemodynamic deterioration, arrhythmias or com-
promised coronary epicardial vessel flow were observed.
Currently no IC delivery strategy has emerged as the optimal administration method for
cell administration. Previous studies have used the stop-flow methodology as described by
Strauer and co-workers [31], with slight variations between these. Briefly, with this technique a
coronary vessel is occluded with an over-the-wire balloon and cells are injected through the
central lumen of the balloon-catheter in several occlusion-reperfusion series. Theoretically this
could avert cell backflow or rapid cell washout. On the other hand, this technique may lead to
MSC accumulation, and even aggregation, increasing the risk of cell entrapping. Another dis-
advantage is the risk of coronary dissection with the balloon, particularly in non-stented ves-
sels. In our experiment, human MSC were slowly infused using a microcatheter and an
infusion pump syringe, at a constant flow and without coronary occlusion. We speculate that
with this approach MSC are drifted towards the microcirculation in smaller numbers and at a
constant rate, which potentially prevents or minimizes microvessel sludging. Our findings sup-
port that this continuous infusion with coronary flow maintained could potentially be a safer
way of IC administration of MSC.
To our best knowledge, the present study is the first one to address the acute microcircula-
tory effects of IC MSC delivery using IMR measurements and a controlled and blind research
design. IMR evaluation relies in a complex technique and our group previously performed its
validation in a porcine model [32].
Here, MSC infusion resulted in a significant, but not so impressive, increase of IMR to
15.3 ± 3 U. This suggests that several degrees of microcirculation compromise could be distin-
guished by IMR assessment, which could be useful towards the establishment of an optimal
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MSC dose scheme to study safety and efficacy. We believe that demonstrating changes in
microcirculation, in vivo and in real time, after the intracoronary administration of these cells
is not trivial, since we still lack the limits on what is normal or what defines an unwanted effect
of any intervention. However, it can be the first step to clarify the potential clinical value of
IMR in future studies.
We also observed a small increase in IMR at 5 minutes in control animals (i.e. no cells
administered) that could be related to coronary manipulation during saline infusion. In fact,
only after 30 minutes, a significant difference between groups occurs. This possibly means that
we should wait before measuring IMR instead of doing it immediately after an intervention to
assess acute effects of any procedure.
Hong and collaborators also addressed the microcirculatory effects of IC injections of adi-
pose-derived stem cells with IMR measurements [30]. These authors reported a significant
increase from baseline in IMR at 7 days in the high-dose group (receiving 50x106 cells)
(11 ± 1.3 vs. 17.8 ± 3.2, p = 0.04, respectively), and no significant changes in the low-dose
group (10x106 cells). Despite the different MSC source (adipose) used and a distinct IC infu-
sion technique (i.e. cells were delivered at a rate of 1.3 ml/min with alternating 3-min infusions
and 3-min periods of reperfusion), our results are in line with those obtained by Hong and co-
workers, which clearly demonstrates the potential for microvasculature obstruction with MSC
IC delivery. The differences observed between the two studies, namely the more expressive
increase in IMR observed in our work might be also the result of differences in the studied pop-
ulation (healthy vs. post-myocardial infarction animals), and time of IMR assessment. In con-
trast to the previous work, our operators were blinded for the assessment of IMR, which avoids
operator-induced bias.
Most importantly, CFR had no significant change, confirming that epicardial circulation
was unaffected during the experiment and that IMR is a better and more specific parameter for
microcirculation assessment.
Study Limitations
We used healthy animals with normal microcirculation and extrapolating our results to the
context of heart disease should be done with caution. A histological study to confirm the pres-
ence of microvessel obstruction was not performed, and so we can only consider this as a
hypothesis for the occurrence an increase in IMR. On the other hand, a side-by-side compari-
son between IC infusion techniques was not done and thus our results warrant further
research.
Overall, IMR enables the assessment of the microcirculation status by Interventional Cardi-
ologists. Correlating IMR values after IC delivery of MSC with data about cell fate and distribu-
tion, histological analysis and long term clinical benefit in the context of heart disease are
important issues that should be addressed in future work.
Conclusion
We demonstrate the feasibility of use IC delivery to administer culture-expanded human MSC
without compromising hemodynamic, electrical stability and epicardial coronary flow. How-
ever, our study does provide definitive evidence of microcirculatory disruption exposed by a
significant increase in IMR. The impact of these microcirculatory effects and the potential
applications of IMR warrant further investigation.
Intracoronary Delivery of Human Mesenchymal/Stromal Stem Cells
PLOS ONE | DOI:10.1371/journal.pone.0139870 October 19, 2015 10 / 12
Supporting Information
S1 File. Tables with all the relevant research results.
(ZIP)
Acknowledgments
This work was financially supported by research funds from the Cardiology Department of
Hospital de Santa Marta and by Fundação para a Ciência e a Tecnologia (FCT), Portugal,
through the project EXPL/BIM-MED/1970/2013 CARDIOSAFER and grants SFRH/BD/
90001/2012 and SFRH/BD/51572/2011 awarded to M. F. Mata and I. N. Simões, respectively.
Author Contributions
Conceived and designed the experiments: AF MFM INS CLS. Performed the experiments: AF
MFM SCGMS INS EO BC CLS. Analyzed the data: AF MFM SCG INS BC NC JMSC RCF
CLS. Contributed reagents/materials/analysis tools: AF MFM SCGMS INS EO BC CLS. Wrote
the paper: AF MFM SCG INS BC CLS.
References
1. Mendis S, Puska P, Norrving B editors. Global Atlas on Cardiovascular Disease Preventionand Control.
World Health Organization, Geneva.; 2011.
2. Mozid AM, Arnous S, Sammut EC, Mathur A. Stem cell therapy for heart diseases. Br Med Bull. 2011;
98:143–159.
3. Lopes JP, Fiarresga A, Silva Cunha P, Feliciano J, Cruz Ferreira R. Mesenchymal stem cell therapy in
heart disease. Rev Port Cardiol. 2013; 32(1):43–47.
4. Lennon DP, Caplan AL. Isolation of humanmarrow-derived mesenchymal stem cells. Exp Hematol.
2006; 34 (11):1604–1605.
5. Bunnell BA, Flaat M, Gagliardi C, Patel B, Ripoll C. Adipose-derived stem cells: isolation, expansion
and differentiation. Methods. 2008; 45(2):115–120. doi: 10.1016/j.ymeth.2008.03.006 PMID:
18593609
6. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of
adult human mesenchymal stem cells. Science. 1999; 284(5411):143–147.
7. Patel DM, Shah J, Srivastava AS (2013) Therapeutic Potential of Mesenchymal Stem Cells in Regener-
ative Medicine. Stem Cells Int. 2013; 496218. doi: 10.1155/2013/496218
8. Hansson EM, Lindsay ME, Chien KR. Regeneration next: toward heart stem cell therapeutics. Cell
Stem Cell. 2009; 5:364–377.
9. Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J Cell Biochem. 2006;
98:1076–1084.
10. Eggenhofer E, Franla L, Dahlke M, Hoogduijn. The life and fate of mesenchymal stem cells. Frontiers in
Immunology. 2014; 5:148. doi: 10.3389/fimmu.2014.00148
11. FearonWF, Balsam LB, Farouque HM, Caffarelli AD, Robbins RC, Fitzgerald PJ, et al. Novel index for
invasively assessing the coronary microcirculation. Circulation. 2003; 107(25): 3129–3132.
12. Dos Santos F, Andrade PZ, Eibes G, da Silva CL. Ex vivo expansion of humanmesenchymal stem
cells on microcarriers.Methods Mol Biol. 2011; 698:189–198.
13. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for
defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position
statement. Cytotherapy. 2006; 8(4):315–317. PMID: 16923606
14. Pittenger MF, Martin BJ. Mesenchymal stem cells and their potential as cardiac therapeutics. Cir Res.
2004; 95:9–20.
15. Bartunek J, Behfar A, VanderheydenM,WijnsW, Terzic A. Mesenchymal stem cells and cardiac repair:
principles and practice. J Cardiovas Transl Res. 2008; 1:115–119.
16. Kudo M. Implantation of bone marrow stem cells reduces the infarction and fibrosis in ischemic mouse
heart. J Mol Cell Cardiol. 2003; 35:1113–1119.
Intracoronary Delivery of Human Mesenchymal/Stromal Stem Cells
PLOS ONE | DOI:10.1371/journal.pone.0139870 October 19, 2015 11 / 12
17. Dai W, Hale SL, Martin BJ, Kuang JQ, Dow JS, Wold E, et al. Allogeneic mesenchymal stem cell trans-
plantation in postinfarcted rat myocardium: short- and long-term effects. Circulation. 2005;
112:214–223. PMID: 15998673
18. Kraitchman DL, Heldman AW, Atalar E, Amado LC, Martin BJ, Pittenger MF, et al. In vivo magnetic res-
onance imaging of mesenchymal stem cells in myocardial infarction. Circulation. 2003;
107:2290–2293.
19. Amado LC, Saliaris AP, Schuleri KH, St John M, Xie JS, Cattaneo S, et al. Cardiac repair with alloge-
neic mesenchymal stem cells after myocardial infarction. Proc Natl Acad Sci USA. 2005;
102:11474–11479.
20. Hare JM, Traverse JH, Henry TD, Nabil Dib, RK Strumpf, SP Schulman, et al. A randomized, double-
blind, placebo-controlled, dose-escalation study of intravenous adult humanmesenchymal stem cells
(prochymal) after acute myocardial infarction. J AmColl Cardiol. 2009; 54:2277–2286.
21. Bartunek J, Behfar A, Dolatabadi D, Vanderheyden M, Ostojic M, Dens J, et al. Cardiopoietic stem cell
therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter ran-
domized trial with lineage-specified biologics. J Am Coll Cardiol. 2013; 11; 61(23): 2329–2338.
22. Freyman T, Polin G, Osman H, Crary J, Lu MM, Cheng L, et al. A quantitative, randomized study evalu-
ating three methods of mesenchymal stem cell delivery following myocardial infarction. Eur Heart J.
2006; 27:1114–1122.
23. Perin EC, Silva GV, Assad JAR, Vela D, Buja LM, Sousa ALS, et al. Comparison of intracoronary and
transendocardial delivery of allogeneic mesenchymal cells in a canine model of acute myocardial
infarction. J Mol Cell Cardiol. 2008; 44:486–495.
24. Grieve SM, Bhindi R, Seow J, Doyle A, Turner AJ, Tomka J, et al. Microvascular obstruction by intracor-
onary delivery of mesenchymal stem cells and quantification of resulting myocardial infarction by car-
diac magnetic resonance. Cir Heart Fail. 2010; 3(3):e5–6.
25. Toma C, Wagner WR, Bowry S, Schwartz A, Villanueva F. Fate of culture-expanded mesenchymal
stem cells in the microvasculature: in vivo observations of cell kinetics.Circ Res. 2009; 104:398–402.
26. Vulliet PR, Greeley M, Halloran SM, MacDonald KA, Kittleson MD. Intra-coronary arterial injection of
mesenchymal stromal cells and microinfarction in dogs. Lancet. 2004; 363:783–784.
27. Wang D, Jin Y, Ding C, Zhang F, Chen M, Yang B, et al. Intracoronary delivery of mesenchymal stem
cells reduces proarrhythmogenic risks in swine with myocardial infarction. Ir J Med Sci. 2011;
180:379–385.
28. Houtgraaf JH, De Jong R, Kazemi K, Groot D, Van Der Spoel TG, Arslan F, et al. Intracoronary Infusion
of Allogeneic Mesenchymal Precursor Cells Directly Following Experimental Acute Myocardial Infarc-
tion Reduces Infarct Size, Abrogates Adverse Remodeling and Improves Cardiac Function. Cir Res.
2013; 113(2):153–166.
29. Llano R, Epstein S, Zhou R, Zhang H, Hamamdzic D, KeaneMG, et al. Intracoronary delivery of mesen-
chymal stem cells at high flow rates after myocardial infarction improves distal coronary blood flow and
decreases mortality in pigs. Catheter Cardiovasc Interv. 2009; 73:251–257.
30. Hong SJ, Hou D, Brinton TJ, Johnstone B, Feng D, Rogers P, et al. Intracoronary and retrograde coro-
nary venous myocardial delivery of adipose-derived stem cells in swine infarction lead to transient myo-
cardial trapping with predominant pulmonary redistribution. Catheter Cardiovasc Interv. 2012; 1; 83 (1):
E17–25.
31. Strauer BE, BrehmM, Zeus T, Kostering M, Hernandez A, Sorg RV, et al. Repair of Infarcted Myocar-
dium by Autologous Intracoronary Mononuclear Bone Marrow Cell Transplantation in Humans. Circula-
tion. 2002; 106:1913–1918.
32. Fiarresga A, Selas M, Oliveira E, Cavaco-Gonçalves S, Cacela D, Carrapiço B, et al. Invasive assess-
ment of the coronary microcirculation using the index of microcirculatory resistance: Description and
validation of an animal model. Rev Port Cardiol. 2014; 33:207–212.
Intracoronary Delivery of Human Mesenchymal/Stromal Stem Cells
PLOS ONE | DOI:10.1371/journal.pone.0139870 October 19, 2015 12 / 12
